Select Language:
GLP-1 medications like Ozempic, Wegovy, and Mounjaro are well-known for their roles in weight management and diabetes control. These drugs have gained rapid global popularity recently, as many individuals use them to lower blood sugar, suppress appetite, and address obesity-related health issues.
Emerging research now suggests that these medications might also have an impact on cancer. A new study indicates that GLP-1 drugs may help slow the progression of certain cancers linked to obesity. This research will be presented at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, one of the world’s largest gatherings for cancer research.
The study observed that patients taking GLP-1 treatments appeared less likely to develop metastatic cancer compared to those on DPP-4 inhibitors, commonly called gliptins—a different type of diabetes medication. Metastatic cancer refers to cancer that has spread from its original site to other parts of the body, a stage known as stage IV, which is often more difficult to treat and accounts for many cancer-related fatalities.
Researchers focused on seven types of cancers associated with obesity: breast, prostate, non-small cell lung, colorectal, liver, kidney, and pancreatic cancers. They reviewed medical records from a database containing over 12,000 patients, all of whom were diagnosed with early-stage (I, II, or III) cancer, meaning the disease hadn’t yet spread extensively.
Approximately half of these patients started using GLP-1 drugs after their diagnosis, while the rest continued on gliptins. The GLP-1 drugs studied included liraglutide, semaglutide, tirzepatide, dulaglutide, pramlintide, and lixisenatide. The researchers then compared how many individuals in each group went on to develop stage IV metastatic cancer.
Results showed particularly significant differences for lung, breast, colorectal, and liver cancers. Among these, patients on GLP-1 medications had a 38% to 50% lower risk of developing metastasis compared to those on gliptins. Specifically, lung cancer metastasis occurred in 10% of GLP-1 users versus 22% in gliptin users, and breast cancer spread was 10% versus 20%. For colorectal cancer, rates were 13% on GLP-1 drugs compared to 22%, and for liver cancer, 19% versus 28%.
Additionally, lower rates of metastasis were observed in prostate, pancreatic, and kidney cancers among GLP-1 users, but these findings weren’t statistically definitive yet. Researchers also explored whether the GLP-1 system might directly influence tumors. Some cancer cells contain GLP-1 receptors that respond to the drugs’ signals.
By analyzing data from The Cancer Genome Atlas, they found that tumors with higher levels of GLP-1 receptor expression were associated with a 33% reduced risk of death, particularly notable in breast cancer patients, where the risk decreased by 45%. This suggests that GLP-1 signaling could potentially slow the progression of certain tumors, although the mechanisms remain unclear.
Scientists are considering various hypotheses for how GLP-1 medications might exert anti-cancer effects. These include direct action on cancer cells, modification of the tumor microenvironment, or enhancement of the immune response. Additionally, these drugs could reduce inflammation, improve metabolic health, or alter how cancer cells acquire energy.
Importantly, the study did not observe significant increases in side effects like pancreatitis or stomach inflammation linked to GLP-1 drugs, alleviating some safety concerns.
Lead researcher Dr. Mark David Orland from the Cleveland Clinic emphasized that these findings provide promising early evidence for further investigation. However, he clarified that the study’s observational design cannot establish causality. The team advocates for future randomized controlled trials—the most rigorous research method—to verify whether GLP-1 medications might become part of comprehensive cancer treatment approaches someday.
For those interested in weight management, additional studies explore dietary strategies for fatty liver disease, obesity, and how natural extracts like hop might help reduce abdominal fat. Visitors seeking advice on controlling cravings or boosting metabolism can find recent research offering practical tips and dietary recommendations.
Source: American Society of Clinical Oncology Annual Meeting.
ChatGPT
Perplexity
Gemini AI
Grok AI
